ARO-002 Market Summary

Key Factors Driving ARO-002 Growth

1. Strong Clinical Biomarker Reductions Demonstrating RNAi Potency

Arrowhead’s RNAi platform has consistently shown deep and durable gene silencing across multiple programs.

In Phase II studies of ARO-AAT (later fazirsiran), the company reported:

o 86–93% reductions in circulating mutant Z-AAT protein

o Greater than 80% reduction in liver Z-AAT monomer burden

o Significant improvements in liver injury biomarkers such as ALT reductions of 36–66%.

These results validated the potency of Arrowhead’s TRiM™ RNAi delivery platform and increased confidence in broader pipeline applicability.

2. Large Unmet Need in Rare Liver Diseases

Alpha-1 antitrypsin deficiency (AATD)-associated liver disease currently has no approved pharmacologic therapies specifically targeting the underlying cause of disease progression.

Arrowhead emphasized the “urgent need for new therapeutic options” when the FDA granted Fast Track designation to ARO-AAT.

Rare genetic liver diseases represent attractive commercial opportunities because:

o Patients often require lifelong management

o Orphan-drug pricing can be substantial

o Regulatory incentives may accelerate development timelines

3. Evidence of Histologic and Fibrosis Improvement

Beyond biomarker reductions, Arrowhead demonstrated evidence of actual liver tissue improvement.

Interim biopsy data showed:

o Up to 97% reduction in intrahepatic Z-AAT polymer

o Up to 95% reduction in total liver Z-AAT burden

o Improvements in fibrosis and FibroScan liver stiffness measurements.

Histologic improvement is particularly important because it may correlate with long-term clinical benefit and reduced progression to cirrhosis or liver transplantation.

4. Strategic Partnerships Validate Commercial Potential

Arrowhead partnered with Takeda Pharmaceutical Company for development of ARO-AAT/fazirsiran, providing both financial support and external validation of the platform.

More broadly, Arrowhead has established collaborations with multiple major pharmaceutical companies including:

o Johnson & Johnson

o Amgen

o Novartis

o GSK

These partnerships support long-term growth potential and reduce development risk.

5. Durable RNAi Silencing Enables Infrequent Dosing

Arrowhead’s TRiM™ platform is designed to provide durable gene silencing with infrequent administration, often quarterly or longer between doses.

This creates several commercial advantages:

o Improved patient adherence

o Reduced treatment burden

o Lower healthcare utilization

o Better physician acceptance for chronic diseases

The company continues positioning RNAi therapeutics as potentially superior to therapies requiring frequent injections or infusions.

ARO-002 Recent Developments

In May 2026, ArriVent BioPharma announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ARR-002, a potential first-in-class MUC16/NaPi2b targeting tetravalent antibody-drug conjugate (ADC) with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors.

“ARO-002 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of ARO-002 for potential indication like Acute myeloid leukaemia, Gastrointestinal stromal tumours, and Glioblastoma in the 7MM. A detailed picture of ARO-002’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the ARO-002 for potential indications. The ARO-002 market report provides insights about ARO-002’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ARO-002 performance, future market assessments inclusive of the ARO-002 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ARO-002 sales forecasts, along with factors driving its market.

ARO-002 Drug Summary

ARO-002 is an investigational RNA interference (RNAi) therapeutic candidate developed by Arrowhead Pharmaceuticals in collaboration with Takeda Pharmaceutical Company for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated liver disease. The therapy is designed to selectively silence the mutant Z-alpha-1 antitrypsin (Z-AAT) protein production in hepatocytes using Arrowhead’s proprietary TRiM RNAi platform, thereby reducing the accumulation of misfolded AAT protein in the liver that leads to inflammation, fibrosis, and progressive liver damage. Administered through subcutaneous injection, ARO-002 aims to provide durable suppression of mutant protein expression with potentially infrequent dosing intervals. Early clinical and preclinical studies demonstrated substantial reductions in circulating and intrahepatic mutant Z-AAT levels, along with signals of improved liver health biomarkers, supporting its potential as a disease-modifying therapy for AATD-related liver disease. The drug remains under clinical investigation, with ongoing studies evaluating long-term safety, tolerability, pharmacodynamic effects, and its ability to prevent progression to cirrhosis and liver failure. The report provides ARO-002’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ARO-002 Market Report

The report provides insights into:

• A comprehensive product overview including the ARO-002 MoA, description, dosage and administration, research and development activities in potential indication like Acute myeloid leukaemia, Gastrointestinal stromal tumours, and Glioblastoma.
• Elaborated details on ARO-002 regulatory milestones and other development activities have been provided in ARO-002 market report.
• The report also highlights ARO-002‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The ARO-002 market report also covers the patents information, generic entry and impact on cost cut.
• The ARO-002 market report contains current and forecasted ARO-002 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ARO-002 market report also features the SWOT analysis with analyst views for ARO-002 in potential indications.

Methodology

The ARO-002 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ARO-002 Analytical Perspective by DelveInsight

• In-depth ARO-002 Market Assessment

This ARO-002 sales market forecast report provides a detailed market assessment of ARO-002 for potential indication like Acute myeloid leukaemia, Gastrointestinal stromal tumours, and Glioblastoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ARO-002 sales data uptil 2034.

• ARO-002 Clinical Assessment

The ARO-002 market report provides the clinical trials information of ARO-002 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ARO-002 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ARO-002 Market Potential & Revenue Forecast

• Projected market size for the ARO-002 and its key indications
• Estimated ARO-002 sales potential (ARO-002 peak sales forecasts)
• ARO-002 Pricing strategies and reimbursement landscape

ARO-002 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ARO-002 Market positioning compared to existing treatments
• ARO-002 Strengths & weaknesses relative to competitors

ARO-002 Regulatory & Commercial Milestones

• ARO-002 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ARO-002 Clinical Differentiation

• ARO-002 Efficacy & safety advantages over existing drugs
• ARO-002 Unique selling points

ARO-002 Market Report Highlights

• In the coming years, the ARO-002 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ARO-002 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ARO-002’s dominance.
• Other emerging products for Acute myeloid leukaemia, Gastrointestinal stromal tumours, and Glioblastoma are expected to give tough market competition to ARO-002 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ARO-002 in potential indications.
• Analyse ARO-002 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ARO-002 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ARO-002 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of ARO-002? How strong is ARO-002’s clinical and commercial performance?
• What is ARO-002’s clinical trial status in each individual indications such as Acute myeloid leukaemia, Gastrointestinal stromal tumours, and Glioblastoma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ARO-002 Manufacturers?
• What are the key designations that have been granted to ARO-002 for potential indications? How are they going to impact ARO-002’s penetration in various geographies?
• What is the current and forecasted ARO-002 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ARO-002 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ARO-002 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is ARO-002? What is the duration of therapy and what are the geographical variations in cost per patient?